T-ONE Therapeutics
Business Services · Italy · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Via Pietro Giannone 9, Milano, Lombardy,...Website
www.tonetx.euRevenue
<$5 MillionIndustry
About T-ONE Therapeutics
Is T-ONE Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when T-ONE Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
T-ONE Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if T-ONE Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at T-ONE Therapeutics
Earning: See what the market has to say on T-ONE Therapeutics recently announced quarterly report
Check if T-ONE Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once T-ONE Therapeutics has new funding data
Click to see if T-ONE Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
T-ONE Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
T-ONE Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about T-ONE Therapeutics.
T-ONE Therapeutics Tech Stack
A closer look at the technologies used by T-ONE Therapeutics
Top Business Services Companies
Frequently Asked Questions Regarding T-ONE Therapeutics
T-ONE Therapeutics is focused on developing innovative RNA-based therapies to combat cancer and autoimmune diseases. The company aims to target LINE1 RNA, which is prevalent in T lymphocytes that are dysfunctional in tumor infiltration and inflammatory contexts. By utilizing antisense oligonucleotides (ASO) to modulate LINE1 RNA, T-ONE Therapeutics... Read More